Skip to content

Treatment with Kestose for inoperable pancreatic cancer

Improvement of nutritional condition of the patients with inoperable pancreatic cancer by Kestose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041180151
Enrollment
40
Registered
2019-03-29
Start date
2019-11-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition

Interventions

Improvement of nutritional condition in the patients with inoperable pancreatic cancer

Sponsors

Honda Takashi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed as unresectable pancreatic cancer

Exclusion criteria

Exclusion criteria: 1.Women with pregnancy or possible pregnancy 2.Patients with severe renal failure and heart failure 3.Patient who is considered to be inappropriate for entry into the trial by the investigator 4.Patients with substantial alcohol consumption(20g/day for women or >30g/day for men 5.Patient who is poor in ingestion 6.Patient with other pancreas disease or other cancer 7.Patient who receive other treatments such as chemotherapy,radiotherapy and operation 8.Patients who take nonabsorbable antibiotics

Design outcomes

Primary

MeasureTime frame
Improvement of nutritional condition in the patients with inoperable pancreatic cancer

Secondary

MeasureTime frame
1.Changes of Performance status(KPS) 2.Changes of The European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire(EURTC-QLQ-C30) 3.Changes of total energy expenditure(TEE) 4.Changes of short-chain fatty acid(Butyric acid,Acetic acid,Prorionic acid etc.) 5.Changes of Rapid turnover protein 6.Correlation of gut microbiota and therapeutic effect 7.Metabolome,bile acid and protein analysis of metabolite in feces 8.Correlation between expiratory noble gases,gut microbiota and pancreatic cancer 9.Successful execution rate of Chemotherapy 10.Frequency and degree of side effect 11.Prognosis of inoperable pancreatic cancer

Contacts

Public ContactYoshiyuki Minami

Nagoya University Hospital

minami@med.nagoya-u.ac.jp+81-52-744-2602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026